Burkitt lymphoma is a so-called double-hit lymphoma that is defined by chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent transposition, mainly a t(14 18)(q32;q21) involving BCL2 [ 12].
To the current knowledge, Burkitt lymphoma is a so-called double hit (DH) lymphoma that is defined by a chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent breakpoint, mainly a t(14 18)(q32;q21) involving BCL2.
A number of studies have also investigated various docetaxel/5-FU combinations in patients with recurrent AGC, with response rates ranging from 28% (bolus 5-FU) to 44% (continuous infusional 5-FU), a median TTP of 5.9 months (bolus), and a median overall survival of 7.7 months (bolus) (Constenla et al, 2002; Thuss-Patience et al, 2003).
As would be expected, our results compare favourably with findings on various docetaxel/5-FU combinations in patients with recurrent AGC, where response rates ranged from 28% (bolus 5-FU) to 44% (continuous infusional 5-FU) (Constenla et al, 2002; Thuss-Patience et al, 2003).
Clinical trials were undertaken with imatinib singly or in combination with hydroxyurea, in recurrent meningiomas [ 21, 22].
8– 13, 14, 14 In a landmark Phase III trial that assessed the efficacy of bevacizumab alone or in combination with irinotecan in recurrent glioblastoma, HTN was more frequent in the bevacizumab alone arm.
In a larger multi-institutional phase II trial of bevacizumab alone or in combination with irinotecan for recurrent glioblastoma, 167 patients were randomly assigned to bevacizumab 10 mg/kg every 2 weeks alone or with irinotecan 340 mg/m or 125 mg/m, depending on EIAED status (Table 1).
Hitt et al (2004) evaluated the capecitabine/cisplatin combination in 41 patients with recurrent and/or metastatic squamous HNC, observing an ORR of 68% (RC 39%, RP 29%).
62 Patients with HIGM usually present within the first two years of life with the combination of recurrent respiratory tract infections with encapsulated bacteria and opportunistic infections.
These are promising results and have prompted a phase II study in combination with irinotecan in patients with recurrent glioblastome multiforme [ 24].
